Monopar Therapeutics Inc. (MNPR) Revenue and Competitors
Estimated Revenue & Valuation
- Monopar Therapeutics Inc. (MNPR)'s estimated annual revenue is currently $3.3M per year.
- Monopar Therapeutics Inc. (MNPR)'s estimated revenue per employee is $155,000
Employee Data
- Monopar Therapeutics Inc. (MNPR) has 21 Employees.
- Monopar Therapeutics Inc. (MNPR) grew their employee count by 5% last year.
Monopar Therapeutics Inc. (MNPR)'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO/Co-Founder | Reveal Email/Phone |
2 | Co-Founder and Executive Chairman | Reveal Email/Phone |
3 | Co-Founder and EVP, Research and Development Chief Scientific Officer | Reveal Email/Phone |
4 | Director, Clinical Operations | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Associate Director, Finance and Administration | Reveal Email/Phone |
7 | Sr. Accounting and Reporting Manager | Reveal Email/Phone |
8 | Accounting Associate | Reveal Email/Phone |
9 | Senior Scientist | Reveal Email/Phone |
10 | Program Management Associate | Reveal Email/Phone |
Monopar Therapeutics Inc. (MNPR) Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.6M | 17 | -6% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $2.5M | 16 | 0% | N/A | N/A |
#4 | $803.3M | 3239 | 9% | $1.79M | N/A |
#5 | $2.8M | 18 | 64% | N/A | N/A |
#6 | $38.4M | 248 | 18% | N/A | N/A |
#7 | $2M | 13 | -24% | N/A | N/A |
#8 | $1.4M | 9 | -25% | N/A | N/A |
#9 | $1.4M | 9 | 0% | N/A | N/A |
#10 | $2.5M | 16 | 7% | N/A | N/A |
What Is Monopar Therapeutics Inc. (MNPR)?
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.
keywords:N/A
N/A
Total Funding
21
Number of Employees
$3.3M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Monopar Therapeutics Inc. (MNPR) News
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Growth in Short Interest. Posted by admin on Apr 16th, 2022. Share on Twitter Share on Facebook Share on...
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Rating) saw a significant decline in short interest in the month of March. As of March 15th,...
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical...
Other Companies in Wilmette
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.9M | 26 | 4% | N/A |
#2 | $3.3M | 34 | 3% | N/A |
#3 | $8.6M | 40 | 18% | N/A |
#4 | $5.6M | 40 | 5% | N/A |
#5 | $4.8M | 40 | 0% | N/A |